Effect of leukocyte-reduced platelet-rich plasma on osteoarthritis caused by cranial cruciate ligament rupture: A canine gait analysis model by Vilar, Jos\ue9 M. et al.
RESEARCH ARTICLE
Effect of leukocyte-reduced platelet-rich
plasma on osteoarthritis caused by cranial
cruciate ligament rupture: A canine gait
analysis model
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The goal of this study was to objectively assess the effect of a platelet-rich plasma (PRP)
derivate in English bulldogs with stifle degenerative joint disease secondary to cranial cruci-
ate ligament rupture (CCLR). We used a force platform and affixed electrogoniometers to
measure peak vertical force (PVF), vertical impulse (VI), stance time (ST), and angular
range of motion (AROM), from 12 lame client-owned English bulldogs with post-CCLR stifle
joint abnormalities. The 12 affected subjects were treated with 4 intra-articular injections of
PRP, at 30-day intervals. Ten untreated, sound English bulldogs were used as a reference
group. Clinical outcomes were evaluated using a linear mixed effects model. Mean values
of PVF, VI, ST, and AROM were improved within the first 3 months post-treatment in the
CCLR group, with mean measured changes increasing to maximum 4.56% body weight
gain, 1.5% body weight/second, 0.07 seconds, and 6.18 degrees, respectively. The effects
declined progressively after the treatment interval, ending at nearly initial levels after 6
months. This study demonstrates that dogs with CCLR treated with intra-articular PRP had
improved PVF, VI, ST, and AROM over time; the duration of effect was waning by the end of
the post-treatment period.
Introduction
Cranial cruciate ligament rupture (CCLR) is one of the most significant stifle injuries in domestic
dogs, and is a common cause of chronic lameness [1]. A CCLR results in joint instability leading
to osteoarthritis (OA) and degenerative joint disease [2–6]. Progressive joint degeneration pro-
duces changes in catabolic and anabolic activity of chondrocytes [7], impairing functional capabil-
ity, producing pain, limiting flexibility and motion and lowering quality of life [8].
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Various surgical techniques have been advocated to treat CCLR, including extracapsular
stabilization, tibial plateau-leveling osteotomy, and tibial tuberosity advancement [9]. Conser-
vative management includes weight loss [10], omega-3 fatty acid supplementation [11] and
use of NSAID drugs [12].
Recently, innovative treatments for modulating joint pain have been introduced, including
chemical precursors, mesenchymal stem cell therapy, and growth factors obtained from plate-
let-rich plasma (PRP). These treatments can be used alone or in combinations [6,13]. Platelets
have high concentration of growth factors, making PRP an appealing therapeutic alternative.
The platelet growth factors could favorably influence need for analgesia, soft tissue healing, reg-
ulation of anti-inflammatory signals [14], and vascularizing and innervating of autografts [15].
Based on experimental results, PRP alone or as a co-therapy with surgical repair, can reduce
progression of OA, without undesirable side effects [16,17]. It can be difficult to compare ther-
apeutic studies directly because of differing assessment criteria, clinical measures (ie, OA clas-
sification systems), inclusion and exclusion criteria, varying aetiologies or the many possible
intrinsic patient factors. Thus, objective measures of level and duration of efficacy represent
significant advancements in experimental methods [18].
Force platform gait analysis is an objective, quantitative, non-invasive, and reliable method
to characterize ground reaction forces during locomotion [19,20]. This kinetic methodology
has been used to characterize gait in dogs after CCLR [1], but not for objective assessment of
the effect of PRP in dogs with stifle OA that is secondary to naturally-occurring CCLR. On the
other hand, electrogoniometers have been used to measure dog joint metrics such as range of
angular movement (AROM) [21].
We hypothesize that PRP therapy has beneficial effects in dogs with CCLR, but that this
effect may be limited in terms of time. To test this hypothesis, we used force platform and elec-
trogoniometric gait analysis to determine efficacy and duration of effect of PRP therapy in
English bulldogs with unilateral CCLR. An additional goal was to estimate an initial dosing
regimen for further research.
Materials and methods
Dogs
All procedures were approved by the Ethics Committee of the Research Institute in Biomedical
and Health Sciences of the University of Las Palmas de Gran Canaria (Spain), in compliance
with national (Royal Decree 1201/2005) and European Union regulations (European Directive
86/609/CE) for projects using animals for research. A total of 22 adult, client-owned English
bulldogs were included in the study. Ten of them served as clinically normal, unaffected,
untreated control group. General inclusion criteria consisted of body weight between 18–27 kg
and age between 1.5–6 years.
CCLR group. To qualify for our study design, post-CCLR dogs (n = 12) would be overtly
lame on the ipsilateral injury side and would lack evidence of concurrent systemic or other
orthopaedic disease. Medical screening included hematology, urinalysis, serum biochemical
profiles, and no medication given over the preceding 4 weeks. All dogs were evaluated for
articular effusion and for tibial compression and cranial drawer tests to assess the integrity of
the cranial cruciate ligament.
Bilateral stifle radiographs were made under tibial compression with each dog in ipsilateral
recumbency. CCLR was confirmed by observing cranial displacement of the proximal end of
the tibia with respect to the femoral condyles, and any radiographic signs that were consistent
with osteoarthritis. The radiological and physical evaluations also were needed to confirm that
the stifle joint disease was unilateral.
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Control group. The dogs selected for the Control group (n = 10) would not have current
or previous history of orthopaedic or neurologic disease, nor persistent injury or systemic dis-
ease, confirmed by general physical examination, orthopedic evaluation, and radiology. None
of the control dogs were forced to perform physical activities. Dog owners signed an informed
consent form that allowed their dogs to participate in the study.
Preparation and administration of PRP
Prior to platelet collection and activation, blood platelet and leukocyte counts were obtained.
Whole blood (10 mL) was extracted aseptically from a cephalic vein and collected in two 5-mL
centrifuge tubes, each containing 1.0 mL sodium citrate (2.5% solution) as anticoagulant. The
tubes were centrifuged (Centronic JP selecta, model 7000015, Barcelona, Spain) for 10 min at
210 x g. Only the lower one-third of the yielded plasma (adjacent to the buffy coat) was acti-
vated with 5% of its volume, using 10% calcium chloride. The resultant ~2 mL solution was
injected aseptically into the affected stifle joint through the conventional arthrocentesis site
[22]. The appearance of joint fluid confirmed proper needle placement. A total of four doses
were administered on days 0, 7, 14 and 21. After each inoculation, exercise was restricted for 2
days by confining to a walk at a maximum of 30 minutes/day on a leash. For the remaining
days, dogs could walk on a leash a maximum of three times daily for 30 minutes, until the end
of the experiment. No dogs were engaged in strenuous activity during the study.
Gait analysis
Kinetic analysis was performed using a single platform mounted in the centre of, and level
with, a 7-m runway covered by a rubber mat. The mat weight was eliminated by setting it to “0
force” with the tare button, after the platform was covered. Dogs were leash-guided at a walk
over the force platform, always by the same handler. Walk velocity was measured using a
motion sensor (Pasco, Roseville, California, USA) positioned 1-m from the platform.
Five valid trials were obtained for each dog, at a sampling frequency of 250 Hz. A trial was
considered valid when the limb fully contacted the force platform and the dog walked next to
the handler without pulling on the leash. The trial was discarded if the dog was distracted dur-
ing the measurement, if the limb struck the edge of the force plate, or if any portion of the con-
tralateral paw hit the force plate. A member of the research team (OR) evaluated the trial to
confirm which limb touched the centre of the force platform. The platform was interfaced
with a dedicated computer using DataStudio (Pasco, Roseville, California, USA), a software
specially designed for acquisition, numerical conversion, and storage of data. A team member
(JMV) recorded data from affected limbs at Day D0, D30, D90 and D180 after the first admin-
istration of PRP. Data from sound dogs were obtained at the same intervals; the Peak Vertical
Forces (PVF) and Vertical Impulse (VI) values were normalized to body weight (as %) to char-
acterize possible improvement of lameness during treatment with PRP. The Stance Time (ST)
value was acquired directly from DataStudio.
Immediately after the force platform examination, electrogoniometry was performed using
an electrogoniometer (Pasco) placed over the lateral collateral ligament of the stifle and affixed
with adhesive plasters by an experienced researcher (OR). After the dogs were observed to be
comfortable with the device, five consecutive steps were recorded. Electrogoniograms were
obtained with the same software used to obtain the AROM.
Statistical analysis
The purpose of the experiment was to determine if systematic differences exist in PVF, VI, ST
and AROM in dogs with CCLR under PRP treatment given at four fixed moments in time: D0,
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D30, D90, D180. For this reason, a linear mixed effects model was used with the experimental
factor (time) as a fixed effect and the blocking factor (dog) as a random effect. The model is as
follows:
yijk ¼ mj þ bi þ bij þ mijk; i ¼ 1; . . . ; 5; j ¼ 1; . . . ; 4; k ¼ 1; . . . ; nij
bi  Nð0; sbÞ; bij  Nð0; slÞ; mijk  Nð0; sÞ
where yijk is the k-th measure of PVF, VI, ST and AROM, for the dog (i = 1 . . . 5) on day j = 1
(0), 2 (30), 3 (90), and 4 (180); μj is the (fixed) effect of time j. This parameter represents PVF,
VI, ST, and AROM in the CCLR group, at the j-th observation. For bi, the (random) effect of
dog, values are anticipated to be normally distributed, with mean 0 and standard deviation σb.
Thus, σb is the variability in the response due to the dogs; is the interaction effect between dog
and time of observation (j). This term allows for the possibility that some dogs could improve
at the same time period as others worsen. μijk is the residual in the measure ijk. This variable
also is assumed to be normally distributed with mean 0 and standard deviation σ. ηij is the
number of replicates of the PVF, VI, ST and AROM, measures on the dog at each time
interval.
Metrics in this model were estimated using the nlme package in R statistical software
(https://www.r-project.org/). For comparing fixed effects, the multiple comparison test of
Tukey was applied. For assessing the validity of the model, a Shapiro-Wilk test was applied for
testing normality of the residuals, and a Levene’s test was done for testing homoscedasticity.
Ninety-five percent confidence intervals for differences between CCLR and Control groups at
serial intervals also were computed. Statistical power analysis was calculated with Glimmpse©
(http://glimmpse.samplesizeshop.org/#/).
Results
The CCLR group contained 4 female and 8 male dogs, and the Control group consisted of 4
female and 6 male dogs. The mean (± SD) body weight of enrolled dogs was 22.83 ± 2.62 kg in
the CCLR group and 23 ± 3.01 kg in the Control group (P = 0.30). Mean age was 3.6 ± 1.14 in
the CCLR group and 4 ± 1.22 in the Control group (P = 0.54).
The mean value for walking velocity of both sound (Control) and CCLR group dogs was
0.7 ± 0.2 m/s (P = 0.12). Mean values (± SD) for PVF, VI, ST and AROM, in both CCLR
and Control groups are summarized in Table 1. Data were distributed normally and were
homoscedastic.
The PRP obtained under this protocol revealed mean platelet count of 1013 ± 431 x 103
cells/μL ( 336% baseline count) and mean leukocyte count of 0.1 ± 0.1 x 103 cells/μL
(Table 2).
Analysis of PVF
Comparing with D0, mean PVF in the CCLR group increased by 4.56% at D30 (P< 0.0001);
3.34% increase was found at D90 (P < 0.0001); and 0.97% increase at D180 (P = 0.0077).
Compared with the Control group, lower PVF was found at D0 (4.96%) (P < 0.0001) and
D180 (3.57%) (P< 0.0001) (Fig 1).
Analysis of VI
VI was increased 1.5% at D30 (P< 0.0001), 0.9% at D90 (P< 0.0001), and 0.4% at D180, all as
compared with day 0 (P = 0.003).
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Comparison of the CCLR and Control groups revealed significant differences at D0 (1.13%
less) (P< 0.0001), and at D180 (0.63% less) (Fig 2) (P < 0.0001).
Analysis of ST
In the CCLR group, with respect to D0, ST increased in 0.07s, 0.04s, and 0.03s at D30 (P = 0),
D90 (P = 0), and D180 (P = 0.004224), respectively.
Compared with Controls, affected dogs’ ST was 0.05s less at D0 (P = 9.1–9). At D30, the dif-
ference was not significant. At D90 and D180, ST again was lower (0.044s and 0.019s, respec-
tively) (P = 0.039) (Fig 3).
Analysis of AROM
Analysis of variance revealed that at D30, AROM increased by 5.68 degrees, compared with
D0 (P < 0.0001). AROM increased to 6.18 degrees at D90 (P< 0.0001).
Compared with the Control group, CCLR dogs had AROM 6.48 degrees less at D0
(P< 0.0001); at D30 and D90, no differences were found. However, at D180, AROM decreased
by 6.17 degrees (P< 0.0001) (Fig 4).
Our sample size of 12 dogs provided a statistical power of 83% for the detection of differ-
ences of 0.5% of each parameter among individuals.
Discussion
We assessed PVF, VI, ST, and AROM changes in lame English bulldogs with unilateral CCLR
treated with PRP. We used a force platform and electrogoniometry. The data provided support
our hypothesis that PRP therapy is effective for OA secondary to CCLR, although the effect is
temporary.
To our knowledge, this is the first study that provides objective data regarding PRP treat-
ment outcomes in dogs with sequelae to naturally occurring CCLR.
Table 1. Mean and standard deviation (mean ± SD) of force plate analysis data (n = 22) for the lame leg in CCLR group and Control group. Data are shown in per-
cent of dog weight (PVF, VI), in seconds (ST), and degrees (AROM).
Parameter Day after treatment
D0 D30 D90 D180 SWT LT
PVF 0.09 0.7
CCLR 35.13 ± 1.08# 39.69 ± 1.10 38.47 ± 1.31 36.10 ± 0.78#
Control 40.09 ± 0.84 39.34 ± 0.66 39.32 ± 0.76 39.37 ± 0.51
VI 0.20 0.40
CCLR 10.79 ± 0.61# 13.28 ± 0.66 11.69 ± 0.55 11.19 ± 0.62#
Control 11.90 ± 0.60 11.89 ± 0.65 11.95 ± 0.58 11.82 ± 0.46
ST 0.37 0.60
CCLR 0.38 ± 0.03# 0.45 ± 0.05 0.43 ± 0.03# 0.40 ± 0.03#
Control 0.43 ± 0.03 0.44 ± 0.04 0.45 ± 0.03 0.43 ± 0.03
AROM 0.82 0.45
CCLR 25.10 ± 3.15# 30.78 ± 1.96 31.25 ± 1.56 25.49 ± 3.67#
Control 31.58 ± 0.61 31.51 ± 0.62 31.62 ± 0.69 31.67 ± 0.58
PVF = peak vertical force, CCLR = cranial cruciate ligament rupture group, VI = vertical impulse, ST = stance time, AROM = angular range of motion
# significant difference (p<0.05) between study and Control group.
 significant difference (p<0.05) in the study group between checking periods and D0, SWT Shapiro-Wilk test value, LT Levene test value.
https://doi.org/10.1371/journal.pone.0194752.t001
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PRP therapy was demonstrated to have a positive effect on limb function. Specifically, we
observed improved locomotion, associated with reducing both lameness and gait disability,
allowing the dogs to support more weight on their hind limbs and reach greater AROM.
Important factors that make it difficult to compare results among studies are the diverse
methods and devices used to evaluate pain and lameness. In this sense, PRP joint therapy
requires more investigation, focused specially on assessing its efficacy across therapies, using
objective, and reliable assessment tools.
When kinetic evaluation is performed, some authors state that the force plate gait analysis
yields large variation in normal ground reaction forces, preventing meaningful direct compari-
son of data among different dogs or among dog groups having differing conformation (breed)
[23]. Under this premise, comparative studies necessarily require rescaling, harmonization, or
normalization of data. In our study, we chose all dogs of the same breed to provide more stan-
dardized data sets.
Regarding ST, a kinematic parameter, one report indicated that a group of dogs treated
with NSAIDs experienced decrease in ST when they were able to improve their performance
[24]. However, other reports indicate that ST remained unchanged or increased as limb func-
tion improved [25,26]. If pain is suppressed effectively, we suggest that ST should improve
after effective treatment.
Table 2. Weight and platelet count for each dog at D0, D30, D90 and D180.
Weight
Day after treatment
D0 D30 D90 D180
CCLR
Dog 1 19 284 296 270 280
Dog 2 21 331 314 314 313
Dog 3 23 458 488 410 435
Dog 4 25 248 232 253 237
Dog 5 27 367 371 385 342
Dog 6 18 418 423 421 417
Dog 7 23 295 297 293 297
Dog 8 24 318 323 317 323
Dog 9 26 416 423 418 421
Dog 10 23 273 275 278 277
Dog 11 23 346 351 342 353
Dog 12 22 375 384 383 387
CONTROL
Dog 1 23 345
Dog 2 19 464
Dog 3 26 332
Dog 4 21 222
Dog 5 18 337
Dog 6 24 416
Dog 7 27 384
Dog 8 22 295
Dog 9 24 323
Dog 10 26 269
Units; weight: kg, platelets count: 103/μl
https://doi.org/10.1371/journal.pone.0194752.t002
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Fig 1. PVF values in CCLR group at the 6-month follow-up period after treatment with platelet-rich plasma. Data
from Control group also are shown.
https://doi.org/10.1371/journal.pone.0194752.g001
Fig 2. VI values in CCLR group at the 6-month follow-up period after treatment with platelet-rich plasma. Data
from Control group also are shown.
https://doi.org/10.1371/journal.pone.0194752.g002
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Fig 3. ST values in CCLR group at the 6-month follow-up period after treatment with platelet-rich plasma. Data from Control group also are
shown.
https://doi.org/10.1371/journal.pone.0194752.g003
Fig 4. AROM values in CCLR group at the 6-month follow-up period after treatment with platelet-rich plasma. Data from Control group also
are shown.
https://doi.org/10.1371/journal.pone.0194752.g004
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Recent reports have shown that the presence of leukocytes in PRP preparations may be det-
rimental to healing, due to their involvement in the inflammatory response [27] causing loss of
pain relief efficacy [28]. We avoided this complication, because our PRP was prepared with
nearly complete absence of leukocytes.
Concerning actual administration, there is no consensus at this time about a standard regi-
men. Thus, PRP treatment for OA can vary from one to a series of nine injections [29–33].
Under this range of treatment protocols, we decide to apply a mid-level of four injections at
7-day interval.
A follow-up evaluation of 6 months could be considered as a minimum standard for testing
the outcome of a medical or surgical treatment. In our study, this time was sufficient to recog-
nize significant improvement during the first months after treatment, and also to establish that
lame dogs eventually returned nearly to their initial status. The duration of the effect that we
noted is consistent with previous reports [34,35]. Based on our results and taking into account
that improvement by surgical means can extend relief for more than 2 years [29], PRP therapy
may become an alternative resource for those instances wherein affected dogs cannot undergo
surgery because of anaesthetic risk or when dog owners cannot afford surgical costs. Other
commercially available PRP derivates (PRGF- Endoret1, Orthokine1) have been associated
with better effect and/or longer duration, but objectively-generated data remain to be col-
lected, as is the case also with injections of hyaluronic acid or NSAIDs.
Our study has some limitations. First, the number of available dogs was relatively small.
Small sample sizes can associate with low statistical power, and previous reports have estab-
lished that dog conformation and size can affect kinetic measures [23]. Therefore, we decided
to prioritize data homogeneity (diminishing the inter-subject variability) by using dogs from
the same breed within defined weights and ages. We thus noted that variation of only 0.5% in
PVF could be detected with a statistical power of 83%.
Second, although both hind limbs were recorded, we provide only data from the affected
limbs for comparison with control dogs. Based on previous reports, force redistribution to
contralateral limbs and even to forelimbs (in hind limb lameness) could call this choice into
question [36].
Third, our study design included sound dogs as controls when, typically, a Control group
would have included untreated affected dogs. However, painful untreated or placebo-treated
dogs in a positive Control group could worsen, rendering these dogs unable to provide fixed
reference data. Additionally, ethical concerns arise when affected, untreated controls are part
of biomedical experimental designs. In accordance with other authors using similar study
designs [23], data from sound dogs were provided as an “ideal status” disease-free Control
group.
Conclusion
Force platform and electrogoniometric gait analysis established quantitatively that PRP ther-
apy could be useful for treatment of chronic lameness in post-CCLR dogs. Our data indicate
efficacy over a period of 3–6 months, without side effects. Maintaining efficacy for durations
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Sopena, Miguel Batista.
Data curation: Angelo Santana, Oliver Rodriguez.
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